These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26757193)

  • 21. Cognitive function in very old men does not correlate to biomarkers of Alzheimer's disease.
    Velickaite V; Giedraitis V; Ström K; Alafuzoff I; Zetterberg H; Lannfelt L; Kilander L; Larsson EM; Ingelsson M
    BMC Geriatr; 2017 Sep; 17(1):208. PubMed ID: 28886705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease.
    Degerman Gunnarsson M; Lannfelt L; Ingelsson M; Basun H; Kilander L
    Dement Geriatr Cogn Disord; 2014; 37(3-4):196-206. PubMed ID: 24157938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered bidirectional plasticity and reduced implicit motor learning in concussed athletes.
    De Beaumont L; Tremblay S; Poirier J; Lassonde M; Théoret H
    Cereb Cortex; 2012 Jan; 22(1):112-21. PubMed ID: 21572090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired Spike Timing Dependent Cortico-Cortical Plasticity in Alzheimer's Disease Patients.
    Di Lorenzo F; Ponzo V; Motta C; Bonnì S; Picazio S; Caltagirone C; Bozzali M; Martorana A; Koch G
    J Alzheimers Dis; 2018; 66(3):983-991. PubMed ID: 30372679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSF biomarkers predict a more malignant outcome in Alzheimer disease.
    Wallin AK; Blennow K; Zetterberg H; Londos E; Minthon L; Hansson O
    Neurology; 2010 May; 74(19):1531-7. PubMed ID: 20458070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tau and Amyloid β Protein in Patient-Derived Aqueous Brain Extracts Act Concomitantly to Disrupt Long-Term Potentiation
    Ondrejcak T; Klyubin I; Hu NW; O'Malley TT; Corbett GT; Winters R; Perkinton MS; Billinton A; Prenderville JA; Walsh DM; Rowan MJ
    J Neurosci; 2023 Aug; 43(32):5870-5879. PubMed ID: 37491315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired LTD-like motor cortical plasticity in female patients with major depression disorder.
    Yu C; Li A; Li X; Chen Z; Wang P; Dong Z; Daskalakis ZJ; Zhou D
    Neuropharmacology; 2020 Nov; 179():108268. PubMed ID: 32791084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humans with Type-2 Diabetes Show Abnormal Long-Term Potentiation-Like Cortical Plasticity Associated with Verbal Learning Deficits.
    Fried PJ; Schilberg L; Brem AK; Saxena S; Wong B; Cypess AM; Horton ES; Pascual-Leone A
    J Alzheimers Dis; 2017; 55(1):89-100. PubMed ID: 27636847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bradykinesia in Alzheimer's disease and its neurophysiological substrates.
    Bologna M; Guerra A; Colella D; Cioffi E; Paparella G; Di Vita A; D'Antonio F; Trebbastoni A; Berardelli A
    Clin Neurophysiol; 2020 Apr; 131(4):850-858. PubMed ID: 32066104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional correlates of t-Tau, p-Tau and Aβ₁₋₄₂ amyloid cerebrospinal fluid levels in Alzheimer's disease: a ¹⁸F-FDG PET/CT study.
    Chiaravalloti A; Martorana A; Koch G; Toniolo S; di Biagio D; di Pietro B; Schillaci O
    Nucl Med Commun; 2015 May; 36(5):461-8. PubMed ID: 25646706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic neurotransmission dysfunction induced by amyloid-β transforms cortical long-term potentiation into long-term depression and produces memory impairment.
    Moreno-Castilla P; Rodriguez-Duran LF; Guzman-Ramos K; Barcenas-Femat A; Escobar ML; Bermudez-Rattoni F
    Neurobiol Aging; 2016 May; 41():187-199. PubMed ID: 27103531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease.
    Lin YT; Cheng JT; Yao YC; Juo ; Lo YK; Lin CH; Ger LP; Lu PJ
    J Alzheimers Dis; 2009; 18(4):907-18. PubMed ID: 19749420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.